Get the Stockscreener App
45.60
3.42%
1.51
After Hours:
45.60
Exact Sciences Corp stock is traded at $45.60, with a volume of 1.25M.
It is up +3.42% in the last 24 hours and down -3.16% over the past month.
See More
Previous Close:
$44.09
Open:
$44.56
24h Volume:
1.25M
Relative Volume:
0.55
Market Cap:
$8.22B
Revenue:
$2.69B
Net Income/Loss:
$-214.04M
P/E Ratio:
-38.97
EPS:
-1.17
Net Cash Flow:
$98.43M
1W Performance:
+9.67%
1M Performance:
-3.16%
6M Performance:
-35.10%
1Y Performance:
-27.89%
1-Day Range:
$44.08
$45.64
1-Week Range:
$40.80
$46.07
52-Week Range:
$39.97
$72.83
Exact Sciences Corp Stock (EXAS) Company Profile
Name
Exact Sciences Corp
Sector
Industry
Phone
608-284-5700
Address
5505 ENDEAVOR LANE, MADISON, WI
Compare EXAS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
45.60 | 8.22B | 2.69B | -214.04M | 98.43M | -1.17 |
|
TMO
Thermo Fisher Scientific Inc
|
426.66 | 161.38B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
196.50 | 133.67B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
440.98 | 33.35B | 3.90B | 887.87M | 798.08M | 10.67 |
|
A
Agilent Technologies Inc
|
107.02 | 29.22B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
150.68 | 25.37B | 15.41B | 1.37B | 2.11B | 7.50 |
Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Mar-13-25 | Initiated | RBC Capital Mkts | Sector Perform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-27-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Jan-02-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Oct-10-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Aug-02-23 | Downgrade | The Benchmark Company | Buy → Hold |
| May-10-23 | Upgrade | Craig Hallum | Hold → Buy |
| May-05-23 | Initiated | UBS | Neutral |
| Mar-09-23 | Upgrade | Citigroup | Neutral → Buy |
| Feb-10-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| Jan-18-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Oct-19-22 | Downgrade | Craig Hallum | Buy → Hold |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jun-03-22 | Initiated | Piper Sandler | Neutral |
| Nov-03-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jul-29-21 | Reiterated | BTIG Research | Buy |
| Jul-29-21 | Reiterated | Canaccord Genuity | Buy |
| Jul-29-21 | Reiterated | Oppenheimer | Outperform |
| Jul-29-21 | Reiterated | Stifel | Buy |
| Jun-15-21 | Initiated | Raymond James | Strong Buy |
| Jun-03-21 | Initiated | Goldman | Buy |
| May-25-21 | Initiated | Wells Fargo | Equal Weight |
| Jan-28-21 | Initiated | Truist | Buy |
| Oct-29-20 | Downgrade | UBS | Buy → Neutral |
| Oct-28-20 | Downgrade | Citigroup | Buy → Neutral |
| Oct-08-20 | Resumed | BTIG Research | Buy |
| Apr-02-20 | Initiated | Evercore ISI | Outperform |
| Jan-10-20 | Resumed | BTIG Research | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Dec-13-19 | Initiated | Dougherty & Company | Buy |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-17-19 | Reiterated | BofA/Merrill | Buy |
| Oct-01-19 | Resumed | Craig Hallum | Buy |
| Sep-26-19 | Initiated | Oppenheimer | Outperform |
| Feb-26-19 | Upgrade | Goldman | Neutral → Buy |
| Oct-09-18 | Initiated | UBS | Buy |
| Sep-05-18 | Resumed | The Benchmark Company | Hold |
| Aug-13-18 | Reiterated | Canaccord Genuity | Buy |
| Apr-03-18 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-29-18 | Initiated | Goldman | Neutral |
| Jan-08-18 | Reiterated | The Benchmark Company | Buy |
| Nov-13-17 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-01-17 | Downgrade | BTIG Research | Buy → Neutral |
View All
Exact Sciences Corp Stock (EXAS) Latest News
Exact Sciences (EXAS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Yahoo Finance
Exact Sciences (EXAS): Among Billionaire George Soros’ Small-Cap Stocks with Huge Upside Potential - Insider Monkey
Billionaire George Soros’ 10 Small-Cap Stocks with Huge Upside Potential - Insider Monkey
Liquid Biopsy in Cancer Diagnostics Market to Grow at a CAGR of ~17% by 2032 with Advancements in Non-Invasive Testing | DelveInsight - GlobeNewswire Inc.
EXAS Quantitative Stock AnalysisBenjamin Graham - Nasdaq
Exact Sciences Launches New Test To Monitor Cancer Recurrence: Retail’s Optimistic By Stocktwits - Investing.com India
Exact Sciences Launches New Test To Monitor Cancer Recurrence: Retail’s Optimistic - MSN
Exact Sciences launches the Oncodetect MRD test - TipRanks
Exact Sciences (EXAS) Launches Oncodetect Test for Enhanced Cancer Care | EXAS Stock News - GuruFocus
Exact Sciences Launches the Oncodetect™ Molecular Residual Disease Test | EXAS Stock News - GuruFocus
Exact Sciences Launches the Oncodetect™ Molecular Residual Disease Test - Business Wire
Market Sentiment Around Loss-Making Exact Sciences Corporation (NASDAQ:EXAS) - simplywall.st
Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers - Yahoo Finance
Exact Sciences (EXAS) Validates Oncotype DX Test for Diverse Bre - GuruFocus
JAMA Oncology Publication Strengthens Evidence for Oncotype DX® Test Reliability Across Racial and Ethnic Groups - The Joplin Globe
Deep Dive Into Exact Sciences Stock: Analyst Perspectives (8 Ratings) - Benzinga
Mizuho Initiates Exact Sciences at Outperform With $60 Price Target - marketscreener.com
Mizuho sets $60 target on Exact Sciences stock, sees outperform - Investing.com
Mizuho sets $60 target on Exact Sciences stock, sees outperform By Investing.com - Investing.com UK
Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - GlobeNewswire Inc.
10 Promising Biotech Stocks to Invest in (April 2025) - Securities.io
Exact Sciences Schedules First Quarter 2025 Earnings Call - The Joplin Globe
Exact Sciences Launches the Cologuard Plus™ Test, Transforming Colorectal Cancer Screening - BioSpace
Benchmark maintains Buy on Exact Sciences, price target at $65 By Investing.com - Investing.com South Africa
Benchmark maintains Buy on Exact Sciences, price target at $65 - Investing.com
Exact Sciences Positioned for Growth with Upcoming Product Launches and Margin Expansion - TipRanks
High Growth Tech Stocks To Watch In The US March 2025 - Yahoo Finance
Should You Retain Exact Sciences Stock in Your Portfolio Now? - Yahoo Finance
Why Exact Sciences Corporation (EXAS) is Among the Best Diagnostics Stocks to Invest in Right Now - Insider Monkey
12 Best Diagnostics Stocks to Invest In Right Now - Insider Monkey
Exact Sciences (EXAS) Down 10.6% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Should You Invest in Exact Sciences Corp. (EXAS)? - MSN
SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN - Quantisnow
Former Exact Sciences COO Joins Sera Prognostics Board Amid Strategic Expansion - Stock Titan
"Pick Up Your Poop" F Cancer's New Campaign Encourages At-Home Colorectal Cancer Screening - WV News
RBC Capital Initiates Coverage of Exact Sciences (BMV:EXAS) with Sector Perform Recommendation - Nasdaq
Commit To Buy EXACT Sciences At $30, Earn 14% Using Options - Nasdaq
Expert Outlook: Exact Sciences Through The Eyes Of 7 Analysts - Benzinga
PreventionGenetics Assumes the Management of Sponsored Genetic Testing Program for Three Rare Genetic Diseases: Acute Hepatic Porphyria, Primary Hyperoxaluria Type 1 & Hereditary ATTR Amyloidosis - Business Wire
Exact Sciences initiated with a Sector Perform at RBC Capital - TipRanks
Exact Sciences Named 2025 Gallup Exceptional Workplace Award Winner - Joplin Globe
Exact Sciences Triples Industry Average in Employee Engagement, Wins Prestigious Gallup Award - StockTitan
New Data Highlight the Positive Impact of Exact Sciences’ Oncotype DX - Business Wire
Charles Schwab Investment Management Inc. Grows Holdings in Exact Sciences Co. (NASDAQ:EXAS) - Defense World
Exact Sciences Co. (NASDAQ:EXAS) Stake Increased by Jones Financial Companies Lllp - Defense World
3 Top Cancer Biotechs to Keep An Eye On in 2025 - Yahoo Finance
Exact Sciences at Raymond James Conference: Strategic Growth and Innovation - Investing.com
La Paloma CC: Set to host PGA Tour Champions' Cologuard Classic - The First Call
Here’s What Led Artisan Mid Cap Fund to Trim Exact Sciences Corporation (EXAS) - Yahoo Finance
Exact Sciences Corp Stock (EXAS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.98%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):